Table 1.
Vaccines development against Ebola virus under consideration and their clinical trial phase.
| Vaccine | Responsible Party | Location | Clinical Trial Phase | References |
|---|---|---|---|---|
| INO-4212 | Inovio Pharmaceuticals | United states | I | [147] |
| rChAd3-EBOS | NIAID | Uganda | I | [148] |
| DNA plasmid vaccine (VRC-EBODNA012-00-VP) | NIAID | United states | I | [149,150] |
| HPIV3-EBOVZ GP | NIAID | United states | I | [151] |
| HPIV3/ΔHNF/EbovZ GP | NIAID | United states | I | [152] |
| ChAd3-EBO-Z + Ad26.ZEBOV | University of Oxford | United Kingdom | I | [153] |
| rVSVN4CT1-EBOVGP1 | Auro vaccines LLC | United states | I | [146] |
| rChAd3-EBOV + MVA BN-Filo | University of Oxford | Senegal | I | [154] |
| rAd5-EBOV | Sierra Leone-China Friendship Hospital | Sierra Leone | II | [155] |
| rChAd3-ZEBOV | GlaxoSmithKline | Mali and Senegal | II | [156,157] |
| rAd26-EBOV + MVA-BN-Filo + rVSVΔG-ZEBOV-GP | NIAID | Guinea, Liberia, Mali and Sierra Leone | II | [158] |
| VSVG-ZEBOV + ChAd3-EBO Z | NIAID | Liberia | II | [159] |
| MVA-BN Filo + rAd26-EBOV | London School of Hygiene and Tropical Medicine | DRC | III | [160] |
| GamEvac-combi vaccine | Gamaleya Research Institute of Epidemiology and Microbiology | Guinea and Russian Federation | IV | [161,162] |